Dynamic Advisor Solutions LLC boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE: TMO – Get Rating) by 35.8% in the first quarter, Holdings Channel.com reports. The firm owned 4,649 shares of the medical research company stock after acquiring an additional 1,226 shares during the period. Dynamic Advisor Solutions LLC’s holdings in Thermo Fisher Scientific were worth $ 2,746,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. Norges Bank purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $ 2,784,029,000. BlackRock Inc. boosted its stake in shares of Thermo Fisher Scientific by 3.8% during the 4th quarter. BlackRock Inc. now owns 30,982,611 shares of the medical research company stock valued at $ 20,672,838,000 after buying an additional 1,143,333 shares during the last quarter. Marshall Wace LLP grew its position in shares of Thermo Fisher Scientific by 146.4% during the fourth quarter. Marshall Wace LLP now owns 1,043,844 shares of the medical research company stock worth $ 696,497,000 after buying an additional 620,291 shares in the last quarter. Liontrust Investment Partners LLP acquired a new stake in Thermo Fisher Scientific in the third quarter valued at $ 311,726,000. Finally, State Street Corp grew its holdings in Thermo Fisher Scientific by 3.4% during the 4th quarter. State Street Corp now owns 16,223,173 shares of the medical research company stock worth $ 10,828,875,000 after acquiring an additional 529,712 shares in the last quarter. Hedge funds and other institutional investors own 87.48% of the company stock.
TMO opened at $ 513.54 on Wednesday. Thermo Fisher Scientific Inc. has a 1-year low of $ 482.97 and a 1-year high of $ 672.34. The company has a market capitalization of $ 201.03 billion, a price-to-earnings ratio of 26.77, a price-to-earnings-growth ratio of 1.70 and a beta of 0.83. The business has a 50 day moving average price of $ 545.47 and a two-hundred day moving average price of $ 575.65. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.56 and a quick ratio of 1.10.
Thermo Fisher Scientific (NYSE: TMO – Get Rating) last released its earnings results on Thursday, April 28th. The medical research company reported $ 7.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $ 6.17 by $ 1.08. Thermo Fisher Scientific had a return on equity of 25.33% and a net margin of 18.49%. The firm had revenue of $ 11.82 billion for the quarter, compared to analyst estimates of $ 10.66 billion. During the same period in the previous year, the company earned $ 7.21 earnings per share. Thermo Fisher Scientific’s revenue was up 19.3% compared to the same quarter last year. Equities analysts expect that Thermo Fisher Scientific Inc. will post 22.7 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, July 15th. Investors of record on Wednesday, June 15th will be issued a dividend of $ 0.30 per share. This represents a $ 1.20 dividend on an annualized basis and a yield of 0.23%. The ex-dividend date is Tuesday, June 14th. Thermo Fisher Scientific’s payout ratio is 6.26%.
In related news, Director Debora L. Spar sold 200 shares of the company stock in a transaction on Monday, May 2nd. The stock was sold at an average price of $ 544.36, for a total transaction of $ 108,872.00. Following the transaction, the director now directly owns 810 shares of the company stock, valued at $ 440,931.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Michel Lagarde sold 13,030 shares of Thermo Fisher Scientific stock in a transaction dated Friday, May 27th. The shares were sold at an average price of $ 565.04, for a total value of $ 7,362,471.20. Following the transaction, the chief operating officer now directly owns 15,758 shares in the company, valued at approximately $ 8,903,900.32. The disclosure for this sale can be found here. Insiders sold 42,561 shares of company stock worth $ 23,557,413 in the last ninety days. 0.43% of the stock is owned by corporate insiders.
Several analysts have issued reports on TMO shares. StockNews.com assumed coverage on Thermo Fisher Scientific in a research note on Thursday, March 31st. They set a “hold” rating on the stock. Wells Fargo & Company cut Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and reduced their price objective for the stock from $ 605.00 to $ 525.00 in a research note on Monday, April 25th. One analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $ 658.92.
Thermo Fisher Scientific Company Profile: (Get Rating)
Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE: TMO – Get Rating).
Receive News & Ratings for Thermo Fisher Scientific Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Thermo Fisher Scientific and related companies with MarketBeat.com’s FREE daily email newsletter.